Biomedical subjects

R A de Moor

Publications and source records attributed to R A de Moor.

4 recordsLinked to original sources

PubMed2005

[Urinary retention in 2 children after the use of antiemetic agents during acute gastroenteritis].

Two girls, aged 2 and 4 years, with acute gastroenteritis and vomiting, received domperidone and metoclopramide, respectively. Urinary retention developed, but after catheterisation of the bladder was performed once and the medication was withdrawn, both children recovered without further sequelae. Anti-dopaminergic antiemetic agents should be prescribed with caution, especially in young children.

Acute Disease↗

PubMed2003

[Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].

Withdrawal symptoms occurred in a male neonate after maternal use of venlafaxine for depression during pregnancy. The symptoms were restlessness, hypertonia, jitteriness, irritability and poor feeding. The diagnosis was confirmed by a temporary improvement after administration of a low dose (1 mg) of venlafaxine to the boy. Eventually the symptoms began to decline spontaneously, and ceased after 8 days. Exposure to venlafaxine and other antidepressants which inhibit serotonin reuptake during the third trimester of pregnancy carries the risk of a neonatal withdrawal syndrome.

Antidepressive Agents, Second-Generation↗

PubMed2000

Hepatocellular carcinoma in glycogen storage disease type IV.

A 13 year old patient with juvenile type IV glycogen storage disease died of the complications of hepatocellular carcinoma. To our knowledge this is the first reported case of hepatocellular carcinoma in association with type IV glycogen storage disease.

Adolescent↗

PubMed1999

Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis.

Biliary pseudolithiasis has been reported in patients who received ceftriaxone therapy. In addition to biliary sludge formation occasional reports of ceftriaxone-induced nephrolithiasis have been published. In general, these adverse effects will develop after seven to ten days of treatment. We report on a seven-year-old boy with ceftriaxone-associated biliary pseudolithiasis and nephrolithiasis four days after initiation of treatment. Patients receiving a high dose of ceftriaxone and developing colicky abdominal pain should be considered for ultrasound and a change in antibiotic therapy if appropriate.

Bile Duct Diseases↗